Dermatitis News

Silymarin cream may be an effective and tolerable alternative to hydroquinone in patients with melasma, according to a study.

Delgocitinib cream met the primary endpoint in the DELTA 1 pivotal phase 3 clinical trial for the treatment of moderate to severe chronic hand eczema in adults, according to a press release from Leo Pharma.

LOUISVILLE, Ky. — The use of wearable digital health monitors that measure itch and scratch during sleep appeared useful for patients with atopic dermatitis, according to study results.

Patients with moderate to severe atopic dermatitis showed promising results during and up to 20 weeks after treatment in a clinical trial evaluating rocatinlimab, according to a study.

The FDA approved many new drugs in 2022, including a variety of treatments for dermatological diseases and conditions.

LOUISVILLE, Ky. — Patients may worry about how food allergens impact atopic dermatitis, but there often is more to the story, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Ruxolitinib cream demonstrated efficacy and tolerability in patients with atopic dermatitis during 44 weeks of as-needed treatment, according to two phase 3 trials.

Increased exposure to domestic water with high mineral content — or domestic hard water — increased prevalence but not incidence of eczema in adults, according to a study.

Roflumilast cream was an effective and safe treatment for mild to moderate atopic dermatitis in adults and children aged 6 years and older, Arcutis Biotherapeutics announced in a press release.

Serum dupilumab levels showed no correlation to treatment response or adverse events in patients with atopic dermatitis during the first year of treatment, according to a study.